Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pancreatic Neoplasms 16 Colorectal Neoplasms 7 Small Cell Lung Carcinoma 4 Neoplasm Metastasis 4 Stomach Neoplasms 3 Recurrence 3 Cholangiocarcinoma 3 Biliary Tract Neoplasms 3 Sarcoma, Ewing 2 Rhabdomyosarcoma 2 Ovarian Neoplasms 2 Nasopharyngeal Carcinoma 2 Fallopian Tube Neoplasms 2 Triple Negative Breast Neoplasms 1 Somatostatinoma 1 Solid Tumor 1 Small Cell Lung Cancer Extensive Stage 1 Small Bowel Adenocarcinoma 1 Rectal Neoplasms 1 Rectal Cancer Patients 1 Pancreatic Ductal Adenocarcinoma 1 Pancreatic Cancer Non-resectable 1 Pancreatic Cancer Metastatic to Liver 1 Pancreatic Adenocarcinoma 1 PDAC - Pancreatic Ductal Adenocarcinoma 1 Osteosarcoma 1 Neoplasms 1 Neoadjuvant Chemotherapy 1 Metastatic Pancreatic Adenocarcinoma 1 Locally Advanced Rectal Cancer (LARC) 1

Interventions

Everolimus 9 Cisplatin 8 Temozolomide 6 Nivolumab 5 Etoposide 5 Carboplatin 5 Bevacizumab 5 lutetium Lu 177 dotatate 4 Capecitabine 4 pembrolizumab 3 Irinotecan 3 sintilimab 2 dostarlimab 2 cabozantinib 2 azaspirane 2 avelumab 2 atezolizumab 2 Paclitaxel 2 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2 Ipilimumab 2 Immunoglobulin G 2 IFL protocol 2 Fluorouracil 2 Fluorodeoxyglucose F18 2 Disulfides 2 zimberelimab 1 surufatinib 1 selinexor 1 pertuzumab 1 pasireotide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Carcinoma, Neuroendocrine × irinotecan sucrosofate × Clear all

NCT03837977 2024-12-30

NET02

The Christie NHS Foundation Trust

Phase 2 Completed

Neoplasms, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon ⚡